Monitor upcoming product commercialization timelines (e.g., Inzymes' chymosin launch in 2026) and potential milestone payments. The growing partner network may support future revenue diversification, but near-term fundamentals remain weak.
Price Chart
Executive Summary
Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.09 million from $3.50 million in 2024, driven by lower license and milestone revenue. Despite cost reductions in G&A and R&D, the company's net loss widened to $7.36 million. However, the press release highlighted multiple new commercial partnerships and product launches across life sciences and nutrition markets, including the AlbuFree™ DX launch and expanded collaboration with Fermbox Bio.
Key Financial Metrics
Key Facts
- Total revenue decreased to $3.09 million in 2025 from $3.50 million in 2024
- License and milestone revenue dropped to $265,000 from $1.89 million in 2024
- Grant revenue increased to $1.86 million in 2025 due to Gates Foundation and CEPI funding
- Net loss widened to $7.36 million in 2025 from $5.81 million in 2024
- Cash position declined to $8.59 million as of December 31, 2025, from $9.29 million in 2024
- Commercial launch of AlbuFree™ DX with Proliant, OEM deal with IBT Bioservices, and new agreements with BRIG Bio and Inzymes announced
Financial Impact
Revenue down 11.7% YoY; net loss increased by $1.55 million; cash reserves down $700K
Risk Factors
- Continued decline in core licensing and collaboration revenue
- Reliance on future milestone and grant funding to offset operational losses
- Cash burn trend with reserves below $9 million
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262620 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | SC 13G | $0.4194 | awaiting T+20 | — | $0.3929 (−6.32%) |
Sep 25, 2026 4w ago | 8-K | $0.4650 $0.4160 | ▲ +10.54% | ▲ +10.51% | $0.3929 (+15.51%) |
Sep 21, 2026 5w ago | EFFECT | $0.4010 $0.3809 | ▲ +5.01% | ▲ +4.10% | $0.3929 (+2.02%) |
Aug 14, 2026 10w ago | 8-K | $0.7751 $0.4244 | ▲ +45.25% | ▲ +43.25% | $0.3929 (+49.31%) |
Aug 12, 2026 10w ago | 8-K | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.3929 (+55.35%) |
Aug 12, 2026 10w ago | Press Release | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.3929 (+55.35%) |
Jul 24, 2026 13w ago | 8-K | $1.19 $0.6900 | ▼ −42.02% | ▼ −45.64% | $0.3929 (−66.98%) |
Jun 18, 2026 18w ago | DEFA14A | $0.7820 $1.19 | ▼ −52.17% | ▼ −51.64% | $0.3929 (+49.76%) |
May 28, 2026 21w ago | 8-K | $0.7100 $0.8010 | ▲ +12.82% | ▲ +15.96% | $0.3929 (−44.66%) |
Mar 25, 2026 30w ago | Press Release | $0.7000 $0.8600 | ▲ +22.86% | ▲ +12.19% | $0.3929 (−43.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers